Lorne Golub

NIH sees a need for speed in Traverse Biosciences

By GREGORY ZELLER // The National Institutes of Health has welcomed a rising Stony Brook biotech into its competitive Commercialization Accelerator Program. Traverse Biosciences, which is attempting to commercialize novel drug candidates for the treatment of inflammatory diseases affecting animals and humans, has landed one of 80 annual slots in the CAP, a nine-month program hosted by the NIH and the Larta Institute, a California-based networking group promoting international innovation. The NIH CAP – which…


New patent, new partnership for soaring Traverse

By GREGORY ZELLER // When a new U.S. patent is your second-biggest announcement of the day, you’re probably in a good place. It’s all smiles (with healthy teeth, of course) lately at Stony Brook-based Traverse Biosciences, which on Tuesday announced a new patent and a material transfer agreement with what CEO Joseph Scaduto dubbed “a top-10 global animal-health company” – essentially, an agreement to privately test flagship formula TRB-N0224 against a host of animal illnesses. That’s…


Still cutting its teeth, Traverse set for stellar 2017

By GREGORY ZELLER // First, healthy teeth for dogs … then a cancer cure for the world? Financially and otherwise, Traverse Biosciences enjoyed a strong 2016 – but it may ultimately pale compared to what’s shaping up as a potentially enormous 2017 for the Stony Brook biotech and its flagship pharmaceutical. Fueled primarily by a $1.32 million Phase II Small Business Technology Transfer award granted by the National Institutes of Health in August to the…


Traverse CEO Joseph Scaduto

Traverse Biosciences inks R&D, licensing deal

BY GREGORY ZELLER // Stony Brook-based startup Traverse Biosciences has inked an exclusive R&D agreement that could lead to an $8 million sublicensing option. Traverse, a resident of the Long Island High Technology Incubator at Stony Brook University, announced today that it has executed a $250,000 cooperative research and development agreement with Kansas-based Aratana Therapeutics to advance Traverse’s leading drug candidate, TRB-N0224, a potential treatment for periodontal disease in dogs and cats. Traverse Biosciences has…